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Abstract: Prior studies have demonstrated the effectiveness of noninvasive transdermal insulin 
delivery using a cymbal transducer array. In this study the physiologic response to ultrasound 
mediated transdermal insulin delivery is compared to that of subcutaneously administered 
insulin. Anesthetized rats (350–550 g) were divided into four groups of four animals; one 
group representing ultrasound mediated insulin delivery and three representing subcutaneously 
administered insulin (0.15, 0.20, and 0.25 U/kg). The cymbal array was operated for 60 minutes 
at 20 kHz with 100 mW/cm2 spatial-peak temporal-peak intensity and a 20% duty cycle. The 
blood glucose level was determined at the beginning of the experiment and, following insulin 
administration, every 15 minutes for 90 minutes for both the ultrasound and injection groups. 
The change in blood glucose from baseline was compared between groups. When administered 
by subcutaneous injection at insulin doses of 0.15 and 0.20 U/kg, there was little change in the 
blood glucose levels over the 90 minute experiment. Following subcutaneous administration 
of insulin at a dose of 0.25 U/kg, blood glucose decreased by 190 ± 96 mg/dl (mean ± SD) at 
90 minutes. The change in blood glucose following ultrasound mediated insulin delivery was 
−262 ± 40 mg/dl at 90 minutes. As expected, the magnitude of change in blood glucose between 
the three injection groups was dependant on the dose of insulin administered. The change in 
blood glucose in the ultrasound group was greater than that observed in the injection groups 
suggesting that a higher effective dose of insulin was delivered.
Keywords: ultrasound, intensity, drug delivery, insulin, injections
Introduction
Transdermal drug delivery has been studied as an alternative method for noninvasive 
drug administration. However, the use of this method has been limited because the 
superﬁ  cial layer of the skin, the stratum corneum, is not sufﬁ  ciently permeable to 
allow effective transfer of medication into the bloodstream. To enhance transportion 
of drugs through the skin, several approaches, including chemical enhancers (Johnson 
et al 1996), iontophoresis (Wang et al 2005), microneedles (Nanda et al 2006), elec-
troporation (Prausnitz et al 1993, 2004) and ultrasound (Pitt et al 2004; Mitragotri and 
Kost 2004; Smith 2007) have been studied as an alternative to needles. Currently, the 
transdermal transport of insulin is of interest due to the current 21 million Americans 
who have this disease (CEDR 1999; The Whitaker Foundation 2004; Hussain et al 
2007). Diabetes is one of the most costly ailments and its management often requires 
painful, repetitive insulin injections as often as four times each day.
Of the experiments using ultrasound, many were focused on the feasibility of 
the approach (Tachibana and Tachibana 1991; Boucaud et al 2002; Lee et al 2004a). 
Some researchers have studied the effects of frequencies and intensities on the effec-
tiveness of ultrasonic delivery in an effort to understand the mechanisms by which 
ultrasound enhances transdermal delivery (Machet and Boucaud 2002; Merino et al 
2003; Schlicher et al 2006). While ultrasound is effective, the relationship between the International Journal of Nanomedicine 2008:3(3) 336
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intensities and potential bioeffects has yet to be determined 
(Wu et al 1998; Doukas and Kollias 2004). Additionally 
there is limited understanding as how the intensities relates 
to the amount of insulin transported via ultrasound (Luis et al 
2007) or to direct injections. To date, many ultrasound drug 
delivery experiments on enhanced transdermal drug delivery 
are performed using sonicators, ultrasonic baths, or com-
mercially made (“off-the-shelf ”) transducers (Tachibana and 
Tachibana 1991; Santoianni et al 2004; Pitt et al 2004; Smith 
2007). The large sizes of these devices and the difﬁ  culty of 
transporting them have been signiﬁ  cant disadvantages associ-
ated with their practical use for noninvasive drug delivery. 
Commercial sonicators are large, heavy, tabletop devices 
specially designed for lysis of cells or catalyzing reactions. 
In order to become a practical portable ultrasound device, 
there is the need for a smaller transducer which can work in 
the same frequency range (Pitt et al 2004). Additionally it 
is important to balance ultrasound safety (dosimetry) versus 
efﬁ  cacy since large intensities can also cause damage (Wu 
et al 1998; Lee et al 2005).
To meet the demand for a practical portable device, a 
small-sized, low-proﬁ  le, and lightweight cymbal transducer 
has been used for the transdermal delivery of insulin. 
This ﬂ  extensional transducer has a thickness of less than 
2 mm, weighs less than 3 grams and resonates between 
1 and 100 kHz (Newnham et al 1991; Maione et al 2002). 
The cymbal transducer array has previously demonstrated 
enhancement in transport of insulin for in vitro human skin 
(Smith et al 2003a), in vivo rats (Smith et al 2003b), rabbits 
(Lee et al 2004b; Snyder et al 2006), and large pigs (Park 
et al 2007). One of the many questions with this approach is 
the relationship between the levels of glucose decrease from 
ultrasound versus a direct subcutaneous injection of insulin. 
Therefore the purpose of this research is to examine the blood 
glucose response from direct injections of insulin against the 
ultrasound intensity from a cymbal array.
Materials and methods
Ultrasound transducer array
Details regarding the design and construction of the cymbal 
transducer and the multi-element array have been described 
elsewhere (Newnham et al 1991, 1994; Maione et al 2002). 
Brieﬂ  y, the cymbal transducer is a novel ﬂ  extensional trans-
ducer capable of producing very low frequencies (Figure 1a). 
A cymbal transducer has a compact, lightweight structure 
with an adjustable resonance frequency. In the cymbal trans-
ducer design, the caps on the lead zirconate – titanate (PZT) 
ceramic contained a shallow cavity beneath the inner surface. 
The fundamental mode of vibration is the ﬂ  exing of the end 
caps caused by the radial motion of the ceramic. Therefore, 
the overall displacement of the device is a combination of the 
axial motion of the disk plus the radial motion ampliﬁ  ed by 
the end caps. Ampliﬁ  cation factors can be as high as 40 times 
that of the ceramic by itself (Meyer et al 2001). Speciﬁ  cally, 
the piezoelectric disc was made from PZT-4 (Piezokinetics, 
Inc., Bellefonte, PA), had a diameter of 12.7 mm, and was 
1 mm thick. Caps were made of 0.25-mm thick titanium while 
the thin glue layer between the caps and the ceramic disk 
was made of Eccobond® (Emerson and Cuming, Billerica, 
MA) epoxy. For the array, four transducers were connected 
in parallel and encased in URALITE® polymer (FH 3550, 
H.B. Fuller, St. Paul, MN) to produce a transducer array 
arrangement.
The array was driven by a radio frequency (RF) signal 
generated by a pulse/function generator (Model 393, Wavetek 
Inc., San Diego, CA) and ampliﬁ  ed by an RF ampliﬁ  er 
(Model 40A12, Ampliﬁ  er Research, Souderton, PA). The 
electrical impedance of the array was matched to the output 
impedance of the ampliﬁ  er by an external inductor-capacitor 
tuning network. Pulse period, duty cycle, and exposure time 
of the RF signal from the frequency generator was monitored 
using an oscilloscope (Tektronix 2213A, Beaverton, OR). 
For the ultrasound exposure experiments, the array was oper-
ated at 20 kHz with a pulse duration of 200 ms and a pulse 
repetition period of 1 second (ie, 20% duty cycle). Pulsed 
ultrasound was used to avoid damaging either the array or 
the animal’s skin by excessive heat generation.
Ultrasound exposimetry
The intensity was determined according to exposimetry 
guidelines established by the American Institute of Ultra-
sound in Medicine (IEEE 1990; AIUM 1998). For the 
acoustic ﬁ  eld at a plane 1 mm from the transducer face, the 
ultrasonic intensities from the array were measured with a 
calibrated miniature (4 mm diameter) omnidirectional refer-
ence hydrophone (Model TC4013, S/N: 5199093, RESON, 
Inc., Goleta, CA). The cymbal array was submerged in a 
water tank (51 × 54 × 122 cm3) which was made almost 
anechoic by placing 1.27 cm thick rubber sound absorbing 
material around its wall. A custom made degasser, built 
in-house, reduced the dissolved oxygen content of the dis-
tilled water to 1–2 ppm to reduce cavitation effects. Pulse 
period, duty cycle and exposure time of the signal from the 
frequency generator and hydrophone was acquired using an 
Agilent 54622A 100 MHz digitizing oscilloscope (Agilent, 
Palo Alto, CA).International Journal of Nanomedicine 2008:3(3) 337
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Figure 1 (A) For the cymbal array made up of four cymbal transducers, the cymbal elements were connected in parallel, encased in URALITE® polymer and arranged in a two-
by-two elemental pattern. The dimensions of the array were 37 × 37 × 7 mm3 and it weighed less than 20 g. (B) Photograph of a transdermal insulin delivery experiment with 
a rat placed in a dorsal decubitus position with the array attached.  A 1 mm thick water tight standoff was arranged between the abdominal area and the array.   The reservoir 
within the standoff was ﬁ  lled with insulin through a small hole in the back of the array.
A
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Precise, computer-controlled positioning of the 
hydrophone was performed by a Velmex Positioning System 
(Velmex Inc., East Bloomﬁ  eld, NY). Pressure waves detected 
by the hydrophone were recorded by a digitizing oscilloscope. 
A computer-controlled exposimetry positioning system was 
used for automated scanning. The scanning step size for each 
device was 1 mm and the scanning area was 40 × 40 mm2. 
Spatial peak-temporal peak (Isptp) intensity were determined 
over a plane 1 mm from the array face using the hydrophone 
based on three scannings of the array for a mean and standard 
deviation of the intensity results. The intensity of cymbal 
transducer array was Isptp = 102.2 ± 2.3 mW/cm2.
Animal experiments
All procedures described in this report involving live animals 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Pennsylvania State University. 
A total of 16 experiments using eight Sprague-Dawley rats 
(350–550 g) were performed in four experimental groups 
with four rats in each group: one ultrasonic transdermal 
delivery and three subcutaneous injection groups. Rats were 
anesthetized with a combination of ketamine hydrochloride 
(60 mg/kg intramuscularly, Ketaject®, Phoenix, St. Joseph, 
MO) and xylazine hydrochloride (10 mg/kg intramuscularly, 
Xyla-Ject®, Phoenix, St. Joseph, MO). In addition to its role in 
general anesthesia, xylazine was used to induce a temporary, 
but sustained (up to 12 hrs), hyperglycemia in rats (Pavlovic 
et al 1996; Kawai et al 1999).
For the ultrasonic transdermal delivery, the abdominal 
area of the rat was shaved using an electric shaver and a 
depilatory agent was applied to the skin to eliminate any 
remaining hair. After shaving, a 1-mm thick, water-tight 
standoff was attached (Figure 1b) between the skin and the 
array. With the rat in the dorsal decubitus position, a reser-
voir within the standoff was ﬁ  lled with insulin (Humulin® R, 
rDNA U-100, Eli Lilly and Co., Indianapolis, IN) through 
a small hole in the array. Care was taken to remove all 
bubbles from the solution in the reservoir to prevent disrup-
tion of ultrasound transmission. The elapsed time from the 
initial injection of the anesthetic until the start of ultrasound 
exposure was no longer than 25 minutes. For the ultrasound 
exposure, the cymbal array was operated at 20 kHz with an 
Isptp = 100 mW/cm2 for 60 minutes. After the 60 minutes 
ultrasound exposure, the array was removed and the skin 
examined for visible lesions.
The dose of insulin selected for the injection groups 
was based on published insulin doses used to control 
diabetes mellitus in other species and on pilot experiments 
(not reported). Humulin® R Insulin (100 U/ml) was diluted 
with a 0.9% saline solution (Phoenix Pharmaceutical, Inc., 
St. Joseph, MO) to 0.5 U/ml and delivered subcutaneously 
(under the skin of the ventral abdomen) at 0.15, 0.20, or 
0.25 U/kg.
Blood was collected from the tail vein of each rat to obtain 
a baseline glucose level and, following insulin administra-
tion, additional samples were collected every 15 minutes 
for 90 minutes. For the ultrasonic transdermal delivery, the 
base line glucose level was measured at the beginning of 
the ultrasound exposure. The blood glucose level (mg/dl) 
for each sample was determined using the ACCU-CHEK
TM 
blood glucose monitoring system (Roche Diagnostics Co., 
Indianapolis, IN). Each sample was tested at least twice to 
conﬁ  rm the accuracy of the reading.
The data was corrected by subtracting the baseline glu-
cose for each animal from each data point such that only 
changes in blood glucose were compared. Statistical analysis 
was performed using Microsoft Excel® (Microsoft Corp., 
Redmond, WA) and the data of blood glucose versus time 
were pooled for each group and analyzed as the mean and 
standard deviation. A t-test was used to analyze the statistical 
signiﬁ  cance of the differences among the means of groups. 
The p-value was used to determine if the between-group 
differences are signiﬁ  cantly greater than chance.
Results
Results of the ultrasound delivery compared with injection 
doses for the four groups are graphed as the decrease in 
the blood glucose level during the 90 minute experiment 
(Figure 2). Data were graphed and reported as the mean ± 
standard deviation (x ± SD) of each group. Due to the anes-
thesia, the average initial glucose level at the beginning of the 
experiment was 340 ± 69 mg/dl for the 16 experiments. Rats 
not anesthetized with xylazine would have a blood glucose 
closer to a normal level of ~100 mg/dl (Harkness and Wagner 
1995; Hillyer and Quesenberry 1997).
For direct subcutaneous injections with the dose of 
0.15 U/kg and 0.20 U/kg, the blood glucose level deviated 
little from the baseline value. Overall the glucose level 
varied no greater than 32 mg/dl from the initial value over a 
90 minute experimental period for both doses. Yet for a sub-
cutaneous insulin injection of 0.25 U/kg, the blood glucose 
decreased by 190 ± 96 mg/dl after 90 minutes. In compari-
son, the ultrasound produced a blood glucose decrease of 
263 ± 40 mg/dl at 90 minutes. A t-test analysis at 90 minutes 
indicated that all the groups were statistically different from 
each other at a p-level less than 0.01. Visual examination of International Journal of Nanomedicine 2008:3(3) 339
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the skin exposed to ultrasound did not indicate any damage 
or signiﬁ  cant change to the skin.
Discussion
For humans to regulate their blood glucose level, the 
required insulin injection dose is 0.5–1 U/kg/day for adults 
and children and 0.8–1.2 U/kg for adolescents experiencing 
growth spurts (Lance et al 2002; Hodgson and Robert 2006). 
Direct subcutaneous injection doses for animals range from 
0.1–0.4 U/kg subcutaneous (SC) for dogs and 0.1–0.5 U/kg 
(SC) for ferrets (Plumb 2005). Ranges are given since 
physiological variables have a direct effect on the speciﬁ  c 
blood glucose decrease from injections. As many clinicians 
and diabetes patients know, the body's glucose response 
to direct injections varies according to a host of variables 
such as body weight, fat percentage, exercise level, and 
composition of the most recent meal. Consistency of diet and 
exercise along with routine dose-glucose recording aids in 
the control of blood glucose. Without proper glucose control, 
diabetic complications may include renal failure, peripheral 
vascular disease, and limb amputation (Suetsugu et al 2007; 
Meeuwisse-Pasterkamp et al 2008).
To facilitate the ability of a diabetic patient to avoid 
repeated painful daily injections of insulin, a safe, light-
weight, low-proﬁ  le, inexpensive and potentially portable 
ultrasonic device is proposed. The goal was to develop an 
approximate relationship between dose levels from direct 
subcutaneous injections and noninvasive ultrasound at a Isptp 
~100 mW/cm2 for 60 minutes. While an exact mathemati-
cal relationship was not determined, the results in Figure 2 
indicate that the ultrasound dose appears to be greater than 
an injection dose of 0.25 U/kg for rats. Not included in 
the results was a single rat experiment which used a direct 
injection dose of 0.44 U/kg which resulted in a rapid blood 
glucose decrease of 290.5 ± 8 mg/dl after only 60 minutes. 
Given the rapid glucose decrease, the animal was removed 
from the experiment and this dose was determined to be too 
high for the rats. Yet the single point result can indicate that 
the ultrasound dose would be somewhere between injection 
dose levels of 0.25–0.44 U/kg. Nevertheless the results are the 
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Figure 2 Over a period of 90 minutes, the blood glucose level of rats decreased to −262 ± 40 mg/dl at 90 minutes for ultrasound mediated transdermal insulin delivery () 
while there was less than 32 mg/dl change for both 0.15 U/kg (z) and 0.20 U/kg (S) injection groups. For the 0.25 U/kg () injection group, the glucose level decreased to 
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ﬁ  rst steps in determining a relationship between ultrasound 
intensity levels and insulin dose responses. Further experi-
ments should explore the use of larger animals with a similar 
size and weight as humans or animal which are truly diabetic 
such as pancreatectomized pig.
In terms of human diabetes, a person is considered dia-
betic if their blood sugar level is above 126 mg/dl after eight 
hours of fasting. People without diabetes have fasting sugar 
levels that generally run between 70–110 mg/dl. A glucose 
of 110–126 mg/dl is classiﬁ  ed as impaired fasting glucose. 
In the oral glucose tolerance test, 140–200 mg/dl is impaired 
glucose tolerance and greater than 200 mg/dl is considered 
diabetic (Rifkin and Porte 1990; Shaw et al 1999; Carnevale 
Schianca et al 2003). For the last situation a diabetic person 
would need to inject enough insulin to reduce their blood 
glucose by about 100 mg/dl. Both the ultrasound and direct 
injection of 0.25 U/kg achieve blood glucose level decreases 
of 190 mg/dl or greater.
Use of transdermal drug delivery techniques has practical 
clinical application to medications which need to be injected 
multiple times either daily or weekly. A recent review 
on ultrasound drug delivery states that “small-sized low-
frequency transducers need to be developed so that patients 
can wear them” (Pitt et al 2004). As with diagnostic ultra-
sound imaging, drug delivery using therapeutic ultrasound 
requires a delicate balance between safety and efﬁ  cacy and 
requires careful scientiﬁ  c study. For a transdermal device 
to replace conventional needles, the bioeffects and safety of 
each device needs to be carefully evaluated since it will not 
matter how much of any drug can be transported if the skin 
is damaged or the procedure is painful.
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